QRxPharma’s Moxduo Doesn’t Offer Respiratory Safety Advantage, FDA Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee briefing documents state that the fixed-dose combination of immediate-release morphine and oxycodone was not superior to either of its individual components with regard to oxygen desaturation rate.